Following the release of the results, Bell Potter Securities affirmed its $16 target for Mesoblast shares – which is close to three times the current trading price, which has recently hovered around $6.
In a research note, Bell Potter said the plan to conduct a phase II RA trial “adds another high-value, un-partnered programme to Mesoblast, given the high prevalence of RA globally, the US$12 billion global market for existing RA drugs, and the drawbacks of those drugs.”
Mesoblast is also investigating the use of MPCs to treat Type 2 diabetes, and entered the phase II trial stage for this project at the start of the year.
Following the release of the results, Bell Potter Securities...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.010(0.91%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.11 | $1.07 | $4.794M | 4.399M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 14500 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.11 | 141676 | 5 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |